STOCK TITAN
  1. Home
  2. Sec-filings
  3. UNCY
  4. [8-K] Unicycive Therapeutics, Inc. Reports Material Event

Unicycive Therapeutics (UNCY) director Gaurav Aggarwal steps down from board

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Unicycive Therapeutics, Inc. reported that director Gaurav Aggarwal resigned from its Board of Directors effective April 6, 2026.

The company stated that his resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices and expressed gratitude for his service.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Resignation date April 6, 2026 Effective date of Gaurav Aggarwal’s board resignation
Form 8-K regulatory
"FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Board of Directors financial
"resigned from the Board of Directors of the Company"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
false 0001766140 0001766140 2026-04-06 2026-04-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 6, 2026

 

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40582   81-3638692
(State or other jurisdiction of   (Commission File Number)   IRS Employer
incorporation or organization)       Identification No.)

 

1975 W. El Camino Real, Suite 204

Mountain View, CA 94040

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (650) 351-4495

 

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered: 
Common Stock   UNCY   Nasdaq Capital Market 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 6, 2026, Gaurav Aggarwal, a director of Unicycive Therapeutics, Inc. (the “Company”), resigned from the Board of Directors of the Company. Dr. Aggarwal’s resignation was not a result of any disagreement with the Company or its management or Board on any matter related to the Company’s operations, policies, or practices. The Company expressed its gratitude to Dr. Aggarwal for serving on the Unicycive Board of Directors.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: April 6, 2026

 

  UNICYCIVE THERAPEUTICS, INC.
   
  By: /s/ Shalabh Gupta
    Shalabh Gupta
    Chief Executive Officer

 

2

 

Source: View Original Filing on SEC EDGAR

FAQ

What board change did Unicycive Therapeutics (UNCY) disclose on April 6, 2026?

Unicycive Therapeutics disclosed that director Gaurav Aggarwal resigned from its Board of Directors on April 6, 2026. The company noted there was no disagreement related to its operations, policies, or practices and publicly thanked him for his board service.

Did Gaurav Aggarwal resign from Unicycive Therapeutics (UNCY) over a disagreement?

No, Unicycive stated that Dr. Gaurav Aggarwal’s resignation from its Board of Directors was not due to any disagreement. The company specifically mentioned there were no issues regarding operations, policies, practices, or management decisions that led to his departure.

What reason did Unicycive Therapeutics (UNCY) give for director Gaurav Aggarwal’s resignation?

Unicycive Therapeutics did not attribute Dr. Aggarwal’s resignation to any dispute, instead clarifying it was not driven by disagreements. The filing emphasized there were no conflicts over the company’s operations, policies, or practices and included a note of appreciation for his service.

How did Unicycive Therapeutics (UNCY) characterize its relationship with resigning director Gaurav Aggarwal?

Unicycive characterized the relationship positively, explaining that Dr. Aggarwal’s resignation was not related to any disagreements. The company thanked him for serving on the Board of Directors, suggesting a cooperative departure without cited conflicts or governance disputes.

Who signed the Unicycive Therapeutics (UNCY) Form 8-K announcing the director resignation?

Chief Executive Officer Shalabh Gupta signed the Form 8-K on behalf of Unicycive Therapeutics. His signature indicates the company’s official confirmation of Dr. Gaurav Aggarwal’s resignation from the Board and the accompanying statement that no disagreements prompted the decision.

Filing Exhibits & Attachments

3 documents

Other Documents